Barclays lowered the firm’s price target on Sangamo (SGMO) to $5 from $9 and keeps an Overweight rating on the shares. The company’s Q1 call provided additional color on cash runway extended into late Q3 by the capital raise, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGMO:
- Sangamo Biosciences Announces $23 Million Share Offering
- Sangamo Biosciences: Strategic Financial Positioning and Regulatory Advancements Justify Buy Rating
- Sangamo Therapeutics Reports Q1 2025 Progress and Financials
- Sangamo reports Q1 EPS (14c) vs (27c) last year
- Sangamo backs FY25 operating expenses view $135M-$155M
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue